Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.

ABSTRACT:

Objectives

The objective of this study is to assess the trends in treatment selection for patients with de novo metastatic castration-sensitive prostate cancer in the era of upfront combination therapy.

Methods

This multicenter retrospective study included 595 patients treated with either upfront combination therapy (upfront novel hormonal therapies and taxane-based chemotherapy) or vintage therapy (androgen deprivation therapy with or without bicalutamide) between 2016 and 2021. High tumor burden metastatic disease was defined when a patient met the CHAARTED or LATITUDE criteria. We evaluated trends in treatment selection and reasons for selecting vintage therapy.

Results

Of the 595, 123 and 472 patients were classified as having low and high tumor-burden disease, re

SUBMITTER: Miura H 

PROVIDER: S-EPMC11618978 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature